PASH Global has signed an Engineering, Procurement and Construction (EPC) contract with the global healthcare company Fresenius Kabi to build a solar energy system at its pharmaceutical manufacturing site in San Germán, Puerto Rico. The new one-megawatt (MW), ground-mounted solar photovoltaic system will enable Fresenius Kabi to further reduce its environmental footprint by generating its own supply of renewable energy at the site.
The project demonstrates Fresenius Kabi’s commitment to further drive sustainable power generation at its premises. The new solar energy system will generate an estimated 1,504-megawatt hours (MWh) per year to power the healthcare company’s operations, which means that 1,386 megatons (MT) of carbon dioxide (CO2) equivalent per year will be avoided. The project is expected to reach commercial operations by Q3 2022. PASH’s in-house technical and engineering team will be responsible for the entire design and construction. The solar energy system will be built to meet the challenges of hurricanes and windstorms to provide further resilience for Fresenius Kabi’s operations.
The EPC contract was awarded to PASH Global after a competitive tender process. The company will operate and maintain the solar photovoltaic plant at Fresenius Kabi’s manufacturing site in Puerto Rico once construction is completed in order to ensure that electricity production expectations are met.
Kofi Owusu-Bempah, CEO & Managing Partner of PASH Global, said: “PASH is delighted to provide an important sustainable energy solution for Fresenius Kabi to aid in further improving their environmental footprint. PASH has proven experience and track record in delivering solar power system projects in Puerto Rico. We are again the partner of choice for commercial and industrial companies who are serious about reducing their carbon emissions. PASH is committed to energy diversification and sustainability by building more capacity in renewables across the island of Puerto Rico.”
Dr. Christian Hauer, Member of the Management Board of Fresenius Kabi and President of the Transfusion Medicine and Cell Therapies division said: “The implementation of a new solar power system at our manufacturing plant in Puerto Rico is a clear sign of commitment to our environmental responsibility. The photovoltaic technology enables us to generate sustainable energy for our essential transfusion medicine and cell therapies production at San Germán. Thereby, we can provide our lifesaving products for critically and chronically ill patients using renewable energy at the same time. This truly reflects our corporate philosophy of caring for life.”
About PASH Global
PASH Global (PASH) is an impact investor in the clean energy sector. Headquartered in London, PASH was established in 2012 with the intention of using the latest innovations in technology to develop, finance, build, operate and maintain clean energy assets globally. As an impact investor, PASH works to enhance the social and environmental impacts of its Projects. For more information on PASH, visit: https://www.pashglobal.com
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies. https://www.fresenius-kabi.com/us/